Toronto, ON / ACCESSWIRE / February 5, 2015 / CardioComm Solutions, Inc. (EKG.V) ("CardioComm Solutions" or the "Company") a global medical provider of electrocardiogram ("ECG") acquisition and management software solutions, today announced it has entered into a three year renewable, non-exclusive, co-marketing and distribution agreement with Minneapolis based Braemar Manufacturing Ltd., a BioTelemetry company.
Under the agreement, the parties will collaborate to develop and execute on business opportunities in the GSM based wireless ECG event/arrhythmia monitoring market globally. CardioComm Solutions develops and distributes GEMS(TM) WIN and GEMS(TM) AIR ECG software management technologies for use in the ambulatory monitoring of patients, to independent diagnostic testing facilities, hospitals and clinic groups. Braemar engineers, manufactures and sells non-invasive, transtelephonic and GSM enabled wireless ECG recording and arrhythmia detection cardiac monitors. CardioComm Solutions expects to benefit from increased sales of its GEMS(TM) WIN software and from customers upgrading their license to include GEMS(TM) AIR. Additionally, CardioComm Solutions will be provided a per-device fee for sales that are derived though CardioComm Solutions sales leads.
The ambulatory ECG monitoring market is moving towards GSM based transmission of data as traditional analogue telephone services are replaced with digital telecommunications solutions. Also, the capacity for real-time, automatic detection and transmission of data offered by digital GSM enabled ECG monitors increases the monitoring surveillance efficacy for those patients experiencing arrhythmias that occur without symptoms, symptoms that occur during sleep or when a cardiac arrhythmia renders a monitored patient unconscious. Accordingly, the demand for new hardware and software solutions to support this digital device ECG monitoring market is increasing.
CardioComm Solutions recently released its GEMS(TM) (Global ECG Management Solution) WIN software upgrade to the arrhythmia monitoring market. The GEMS(TM) WIN family of products is a Windows 7 and Server 2008 compatible version of the Company's FDA cleared, Health Canada approved and CE Marked ECG management software and includes a module (GEMS(TM) AIR) that enables the use of the Braemar digital wireless event recorders.
The combination of the device and software digital technologies is expected to provide a unique and differentiated offering to the ECG surveillance markets globally. GEMS(TM) WIN will also allow continuedsupport of legacy analogue devices from a large number of manufactures should customers still be maintaining analogue ECG file transfer systems.
The two companies will work together to identify sales opportunities where existing GEMS(TM) clients wish to expand their services to use new digital devices and where current Braemar customers require ECG software solutions that are GEMS(TM) WIN and Server 2008 compatible. CardioComm Solutions will provide GEMS(TM) WIN and GEMS(TM) AIR sales, training and ongoing customer software support while Braemar will provide ongoing the hardware necessary for wireless connectivity, and related warranty and maintenance and customer support relevant to their technologies.
To learn more about the CardioComm Solutions products please see the Company's website www.cardiocommsolutions.com.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Ontario, Canada, with offices in Victoria, B.C.
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: CardioComm Solutions, Inc.